Ingenol mebutate - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for ingenol mebutate and what is the scope of freedom to operate?
Ingenol mebutate
is the generic ingredient in two branded drugs marketed by Padagis Israel and Leo Labs, and is included in three NDAs. There are twelve patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.Ingenol mebutate has thirty-five patent family members in twenty-one countries.
There are three drug master file entries for ingenol mebutate. There is one tentative approval for this compound.
Summary for ingenol mebutate
| International Patents: | 35 |
| US Patents: | 12 |
| Tradenames: | 2 |
| Applicants: | 2 |
| NDAs: | 3 |
| Drug Master File Entries: | 3 |
| Raw Ingredient (Bulk) Api Vendors: | 65 |
| Clinical Trials: | 50 |
| Patent Applications: | 978 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for ingenol mebutate |
| What excipients (inactive ingredients) are in ingenol mebutate? | ingenol mebutate excipients list |
| DailyMed Link: | ingenol mebutate at DailyMed |
Recent Clinical Trials for ingenol mebutate
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Nova Scotia Health Authority | Phase 4 |
| Instituto Nacional de Cancer, Brazil | Phase 1/Phase 2 |
| University of California, San Francisco | Phase 1 |
Generic filers with tentative approvals for INGENOL MEBUTATE
The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.
Anatomical Therapeutic Chemical (ATC) Classes for ingenol mebutate
Paragraph IV (Patent) Challenges for INGENOL MEBUTATE
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| PICATO | Gel | ingenol mebutate | 0.015% | 202833 | 2 | 2016-01-27 |
US Patents and Regulatory Information for ingenol mebutate
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Leo Labs | PICATO | ingenol mebutate | GEL;TOPICAL | 202833-002 | Jan 23, 2012 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Leo Labs | PICATO | ingenol mebutate | GEL;TOPICAL | 202833-001 | Jan 23, 2012 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Leo Labs | PICATO | ingenol mebutate | GEL;TOPICAL | 202833-001 | Jan 23, 2012 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Leo Labs | PICATO | ingenol mebutate | GEL;TOPICAL | 202833-001 | Jan 23, 2012 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ingenol mebutate
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Leo Labs | PICATO | ingenol mebutate | GEL;TOPICAL | 202833-002 | Jan 23, 2012 | ⤷ Sign Up | ⤷ Sign Up |
| Leo Labs | PICATO | ingenol mebutate | GEL;TOPICAL | 202833-002 | Jan 23, 2012 | ⤷ Sign Up | ⤷ Sign Up |
| Leo Labs | PICATO | ingenol mebutate | GEL;TOPICAL | 202833-001 | Jan 23, 2012 | ⤷ Sign Up | ⤷ Sign Up |
| Leo Labs | PICATO | ingenol mebutate | GEL;TOPICAL | 202833-001 | Jan 23, 2012 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
EU/EMA Drug Approvals for ingenol mebutate
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| LEO Laboratories Ltd. | Picato | ingenol mebutate | EMEA/H/C/002275 Picato is indicated for the cutaneous treatment of non‑hyperkeratotic, non‑hypertrophic actinic keratosis in adults. |
Withdrawn | no | no | no | 2012-11-15 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for ingenol mebutate
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| South Africa | 200805187 | Therapeutic compositions | ⤷ Sign Up |
| European Patent Office | 2849742 | PROCÉDÉ DE TRAITEMENT TOPIQUE DE LA KÉRATOSE ACTINIQUE AVEC UN TRAITEMENT CYCLIQUE AU MÉBUTATE D'INGÉNOL (METHOD OF TOPICALLY TREATING ACTINIC KERATOSIS WITH INGENOL MEBUTATE CYCLE THERAPY) | ⤷ Sign Up |
| South Korea | 101451993 | ⤷ Sign Up | |
| European Patent Office | 1988877 | COMPOSITIONS THERAPEUTIQUES COMPRENANT DE L'INGÉNOL-3-ANGELATE (THERAPEUTIC COMPOSITIONS COMPRISING INGENOL-3-ANGELATE) | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for ingenol mebutate
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1988877 | 46/2014 | Austria | ⤷ Sign Up | PRODUCT NAME: INGENOLMEBUTAT; REGISTRATION NO/DATE: EU/1/12/796/001 - 002 20121119 |
| 1988877 | 132014902287215 | Italy | ⤷ Sign Up | PRODUCT NAME: INGENOLO MEBUTATO O UN SUO DERIVATO (SALE O ESTERE)(PICATO); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/12/796/001-002, 20121119 |
| 1988877 | 14C0058 | France | ⤷ Sign Up | PRODUCT NAME: MEBUTATE D'INGENOL; REGISTRATION NO/DATE: EU/1/12/796 20121119 |
| 1988877 | C300682 | Netherlands | ⤷ Sign Up | PRODUCT NAME: INGENOLMEBUTAAT OF EEN DERIVAAT (ZOUT OF ESTER) DAARVAN; REGISTRATION NO/DATE: EU/1/12/796 20121119 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
